← Back to Search

Statins

Atorvastatin for Mild Cognitive Impairment

Phase 2
Recruiting
Led By Paul Rosenberg, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Not taking statins currently or in the last 6 months.
Be older than 18 years old
Must not have
Taking a statin currently or have taken a statin in the last 6 months.
Contraindications to taking a statin.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether atorvastatin can improve blood flow to the brain in people with mild cognitive impairment.

Who is the study for?
This trial is for people with mild cognitive impairment who have memory or other cognitive issues not caused by another neurological disease. Participants should not be diagnosed with dementia, currently taking statins, or have taken them in the last six months. They must also be able to undergo MRI scans.
What is being tested?
The study tests if Atorvastatin, a medication typically used to lower cholesterol, can improve how well blood vessels in the brain respond and thus potentially increase blood flow in individuals with mild cognitive impairment.
What are the potential side effects?
Atorvastatin may cause muscle pain, fatigue, digestive problems (like constipation or diarrhea), headache, and in rare cases could affect liver function or cause serious muscle damage.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I haven't taken statins in the last 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking or have taken a statin in the past 6 months.
Select...
I cannot take statin medications due to health reasons.
Select...
I am a transplant patient on cyclosporine.
Select...
I have a history of HIV.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Brain
Secondary study objectives
Change in cognitive function (domain-specific neurocognitive measure)
Body Weight Changes
Change in plasma exosomes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Atorvastatin 40 mgExperimental Treatment1 Intervention
Participants receive 40 mg atorvastatin orally daily in the evening.

Find a Location

Who is running the clinical trial?

The Richman Family Precision Medicine Center of Excellence in Alzheimer DiseaseUNKNOWN
Johns Hopkins UniversityLead Sponsor
2,339 Previous Clinical Trials
14,881,653 Total Patients Enrolled
Paul Rosenberg, MDPrincipal InvestigatorJohns Hopkins University
3 Previous Clinical Trials
246 Total Patients Enrolled
Sevil Yasar, MD, PhDPrincipal InvestigatorJohns Hopkins University

Media Library

Atorvastatin (Statins) Clinical Trial Eligibility Overview. Trial Name: NCT04765137 — Phase 2
Mild Cognitive Impairment Research Study Groups: Atorvastatin 40 mg
Mild Cognitive Impairment Clinical Trial 2023: Atorvastatin Highlights & Side Effects. Trial Name: NCT04765137 — Phase 2
Atorvastatin (Statins) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04765137 — Phase 2
Mild Cognitive Impairment Patient Testimony for trial: Trial Name: NCT04765137 — Phase 2
~3 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top